Lowenstein Sandler represented Inductive Bio in $25 million Series A financing to transform small molecule drug discovery with an industry-wide AI platform. Obvious Ventures led the funding round with participation from Andreessen Horowitz (a16z) Bio + Health, Lux Capital, S32, Character, and Amino Collective, as well as participation from angel investors Oren Etzioni, Jeff Hammerbacher, Malay Gandhi, and Jakob Uszkoreit.
Inductive intends to use the funding to expand its AI model R&D, grow its pre-competitive data consortium, and deploy its technology industry-wide, thus leveling the playing field for both innovative startups and large pharmaceutical companies. In the long term, the company plans to launch an AI-native contract research organization on top of its technology.
The Lowenstein team included Eric Weiner, Frank W. Eucalitto, Jun Hyon “Henry” Nahm, and Sophia Yi-Hun Kim.
